MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering.

Piper Jaffray & Co. is acting as the sole book-running manager for the offering.

About Novan

Novan, Inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. We believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.